Search

Displaying results 4701 - 4710 of 10000 in total
  1. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). … CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.

  2. Drug

    EW-A-401

    go.drugbank.com/drugs/DB05525
    Investigational

    EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.

    Synonyms: EW-A-401 DNA Plasmid Vector
  3. Drug

    Bambuterol

    go.drugbank.com/drugs/DB01408
    Investigational

    Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.

  4. Drug

    Epitizide

    go.drugbank.com/drugs/DB13989
    Experimental

    Epitizide is an agent, commonly found in combination [triamterene], used to produce diuresis.

  5. Drug

    Lixudebart

    go.drugbank.com/drugs/DB19244
    Investigational

    Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.[L50833]

  6. Drug

    P-nitrobiphenyl

    go.drugbank.com/drugs/DB12300
    ApprovedWithdrawn

    Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.

  7. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  8. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  9. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  10. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability … , and oral availability; all of these have met the requirements of an ideal oral drug candidate.